Dynamics of JAK2 V617F allele burden of CD34+ haematopoietic progenitor cells in patients treated with ruxolitinib.
A Angona, A Alvarez‐Larrán… - British Journal of …, 2016 - search.ebscohost.com
A Angona, A Alvarez‐Larrán, B Bellosillo, R Longarón, C Fernández‐Rodríguez, C Besses
British Journal of Haematology, 2016•search.ebscohost.comThe article presents a study indicating that ruxolitinib had clinical benefit in terms of
reduction of the spleen size in spite of a minimal effect on the JAK2 V617F mutant allele
burden of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). It
mentions how the presence of mutations in additional genes other than JAK2 V617F may
play a role in the transformation of chronic phase polycythaemia vera (PV) and myelofibrosis
(MF) to acute leukaemia.
reduction of the spleen size in spite of a minimal effect on the JAK2 V617F mutant allele
burden of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). It
mentions how the presence of mutations in additional genes other than JAK2 V617F may
play a role in the transformation of chronic phase polycythaemia vera (PV) and myelofibrosis
(MF) to acute leukaemia.
Abstract
The article presents a study indicating that ruxolitinib had clinical benefit in terms of reduction of the spleen size in spite of a minimal effect on the JAK2 V617F mutant allele burden of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). It mentions how the presence of mutations in additional genes other than JAK2 V617F may play a role in the transformation of chronic phase polycythaemia vera (PV) and myelofibrosis (MF) to acute leukaemia.
search.ebscohost.com